Table 1.
Predisposing factors for chemotherapy-induced nephrotoxicity – Univariate analysis
| Nephrotoxicity (n = 20) | Non-nephrotoxicity (n = 21) | P value | |
|---|---|---|---|
| Age (years) | 65 (56–74) | 65 (51–72) | 0.505 |
| Gender (male/female) | 15/5 | 18/3 | 0.454 |
| Body mass index (kg/m2) | 21.1 (16.6–25.0) | 21.4 (17.8–25.0) | 0.824 |
| Clinical stage (IB/IIA/IIB/IIIA/IIIB/IIIC)* | 2/6/5/2/2/3 | 0/7/1/5/7/1 | 0.335 |
| Performance status (0/1/2) | 10/9/1 | 7/12/2 | 0.266 |
| Cisplatin dose (mg/m2) | 74.5 (40.5–75.2) | 71.9 (43.5–75.0) | 0.171 |
| Concomitant nonsteroidal anti-inflammatory drugs | 2 | 4 | 0.663 |
| Serum albumin level (g/dL) | 4.1 (2.9–4.7) | 3.6 (3.0–4.3) | 0.033 |
| Blood urea nitrogen (mg/dL) | 13.2 (7.0–26.7) | 13.4 (6.4–23.2) | 0.938 |
| Creatinine (mg/dL) | 0.76 (0.39–0.99) | 0.72 (0.46–0.90) | 0.948 |
| Creatinine clearance (mL/min) | 74.5 (63.0–106.4) | 83.1 (65.6–109.1) | 0.010 |
| Estimated glomerular filtration rate (mL/min/1.73 m2) | 79.2 (59.2–124.0) | 83.1 (63.8–114.4) | 0.611 |
| Blood glucose (mg/dL) | 111 (87–169) | 116 (90–181) | 0.374 |
| Hemoglobin A1c (%) | 5.6 (5.3–6.3) | 6.4 (5.5–7.1) | 0.151 |
| Systolic blood pressure (mmHg) | 123 (96–165) | 111 (94–146) | 0.210 |
| Diastolic blood pressure (mmHg) | 70 (51–90) | 72 (53–88) | 0.906 |
| Urine volume for 1 day after chemotherapy (mL) | 4292 (2290–7136) | 4551 (2713–7013) | 0.322 |
| Urine volume for 5 days after chemotherapy (mL) | 18587 (14578–29558) | 22460 (12851–29392) | 0.124 |
*
Union for International Cancer Control, 7th edition. Values are presented as medians (ranges) except for gender, clinical stage, performance status, and concomitant nonsteroidal anti-inflammatory drugs. Statistical comparisons of categorical data between the groups were performed with Fisher’s exact tests or Mann-Whitney U-tests. Statistical comparisons of quantitative data between the groups were performed with Mann-Whitney U-tests.